TRYPTOPHAN DERIVATIVE, PROCESS FOR PREPARING SAME AND A PHARMACEUTICAL COMPOSITION CONTAINING SUCH DERIVATIVE

Abstract: A tryptophan derivative of the formula: wherein R¹ is hydrogen or lower alkyl, and R² is phenyl or lower alkyl-phenyl, or a pharmaceutically acceptable salt thereof and processes for preparing the same are disclos­ ed. Said derivative is useful as a hypolipidemic agent.

Description: Tryptophan derivative, process for preparing same and a pharmaceutical composition containing such derivative. This invention relates to novel tryptophan derivatives, processes for preparing same and a pharmaceutical composition containing such derivatives. More particularly, it relates to Ni -benzylthiocarbonyl-tryptophan derivatives of the formula: EMI1.1 wherein RÚ is hydrogen or lower alkyl and Rê is phenyl or lower alkyl-phenyl, or a pharmaceutically acceptable salt thereof. Hyperlipidemia is known to be one of important causative factors of arteriosclerosis, and various compounds such as dextran sulfate, simfibrate (chemical name: 2-(4 chlorophenoxy)-2-methylpropanoic acid 1,3-propanediyl ester), nicomol (chemical name: nicotonic acid 1,1,3,3-tetraester with 2-nydroxy-1,1,3,3-cyclohexanetetramethanol), clofibrate (chemical name: 2-(4-chlorophenoxy)-2-methylpropanoic acid ethyl ester) and vitamin E nicotinate have been used for the treatment or prophylaxis of said hyperlipidemia. As a result of investigations, it has been found that the tryptophan derivative (I) of the present invention is useful as hypolipidemic agent. In particular, the tryptophan derivative (I) of the invention shows potent hypolipidemic activity without undesirable side effects such as hepatic disfunction. Representative examples of said tryptophan derivative include those of the formula (I) in which R1 is hydrogen or lower alkyl such as methyl, ethyl and propyl; and R2 is phenyl or lower alkyl-phenyl such as 4-methylphenyl, 4ethyl phenyl and 4-isopropylphenyl. Among them! a preferred group of compounds are those of the formula (I) in which R1 is hydrogen or methyl; and R2 is phenyl or 4-methylphenyl. According to the present invention, the tryptophan derivative (I) is prepared by reacting a tryptophan compound of the formula: EMI2.1 wherein R1is the same as defined above, with carbonyl sulfide (COS) and a benzyl halide of the formula: R2CH2X (III) wherein X is halogen and R2 is the same as defined above. Alternatively, the tryptophan derivative (I) may be prepared by reacting the tryptophan compound (II) with a benzylthiocarbonyl halide of the formula: R2CH2SCOX (IV) wherein R2 and X are the same as defined above. The reaction of the compound (II) with carbonyl sulfide and the compound (III) as well as the reaction of the compound (II) with the compound (IV) are accomplished in the presence of an acid acceptor in a solvent. Suitable examples of said acid acceptor include inorganic bases such as sodium hydroxide, sodium carbonate,.sodium bicarbonate and ammonia; and organic bases such as triethylamine, N-methylmorpholine, N,N-dimethylaniline, pyridine and anionic ion exchange resins. Water or a mixture of water and an organic solvent such as tetrahydrofuran, dioxane, acetonitrile, dimethylsulfoxide, N,N '-dimethylformamide, ether, ethyl acetate, methylene chloride or chloroform are suitable as the solvent. The reaction of the compound (II) with carbonyl sulfide and the compound (III) is preferably carried out at a temperature between -300C and 5O0C, especially at a temperature between -100C and 250C. On the other hand, the reaction of the compounds (II) and (IV) is preferably carried out at a temperature between -5O0C and 500C, especially at a temperature between -200C and 250C. In view of the potent hypolipidemic activity of the tryptophan derivative (I) obtained above, said derivative of the present invention is useful for the therapeutic treatment or prophylaxis of various hyperlipidemias such as hypercholesterolemia, hypertriglyceridemia, hyperlipemia and the like. Moreover, the tryptophan derivative (I) of the invention shows less hepatomegaly or other hepatic disorders as compared with clofibrate, and is particularly suitable for treatment of the above-mentioned diseases without such undesirable side effects. Further, the tryptophan derivative (I) has a potent preventive effect upon lipid peroxide formation in living bodies. Lipid peroxide levels in tissues of mammalian species are known to increase with age and cause cell death and/or damage with a consequent change of cell permeability. In addition, lipid peroxides have been suggested to be a primary etiologic factor in the genesis of stroke (cf., "Stroke" Vol. 10, No.3, pates 323 326(1979)). Thus, the tryptophan derivative (I) may be used to improve the lipid peroxide levels in the tissues of aged subjects. The tryptophan derivative (I) can be used for pharmaceutical use in the form of either the free acid or a pharmaceutically acceptable salt thereof. Examples of the pharmaceutically acceptable salts include alkali metal salts such as sodium, potassium or lithium salts; alkali earth metal salts such as calcium or magnesium salts; salts with non-toxic amines such as methylamine, ethylamine, diethylamine, triethylamine, benzylamine, pyrrolidine, piperidine, cyclohexylamine, dicylohexylamine, ethanolamine or diethanolamine; salts with basic amino acids such as ornithine, lysine or arginine; salt with carnitine; and the like. The tryptophan derivative .(I) and a pharmaceutically acceptable salt thereof may be administered either orally or parenterally. For oral administration, said derivative or a salt thereof may be used in the form of tablets, coated -tablets, powder, capsules, granules and the like. Known medicinal excipients such as calcium carbonate, calcium phosphate, corn starch, potato starch, sugar, lactose, talc, magnesium stearate and so forth may be used in making these pharmaceutical preparations. Alternatively, said tryptophan derivative or a salt thereof may be used for oral administration in the form of aqueous or oily suspensions, solutions, syrups or elixirs. On the other hand, injections and suppositories are suitable for parenteral administration of the tryptophan derivative (I) or its salts, and said injections may be made in the form of solutions or suspensions, if required, in conjunction or admixture with distilled water, essential oils (e.g., peanut oil, corn oil) or non-aqueous solvents (e.g., polyethyleneglycol, polypropyleneglycol, lanoline, coconut oil). Concomitantly, while the present invention includes within its scope any one of DL-, D- and L-isomers of the tryptophan derivative (I), L-isomer of said derivative is particularly suitable for pharmaceutical use because of its potent therapeutic effects and less side effects. Practical and presently preferred embodiments of the present invention are illustratively shown in the following lines. Throughout the specification, each compounds of the present invention have been named according to. the "NOMENCLATURE OF d-AMINO ACIDS" described in "Biochemistry" 14 (No. 2), 449-462 (1975). EXPERIMENTS (Methods) (°) Hypolipidemic activity: A test compound (0.10 w/w %) was added to a commercial diet, and male SD rats (body weight: 120 - 140 g , a group of 6 rats) were maintained on the diet for one week. After the experimental period, blood was collected from the tail vein of the rats under ether anesthesia. Thereafter, the liver was excised and weighed. Serum cholesterol and serum triglyceride were measured according to the methods of Zak (Amer. J. Clin. Pathol., Vol. 24, page 1307 (1954)) and Van Handel Zilversmit (J. Lab. & Clin. Med., Vol. 50, page 152 (1957)), respectively. Then, the increase (%) in liver weight and the decrease (%) in serum cholesterol or triglyceride were calculated according to the following formulae: EMI6.1 <tb> <SEP> Serum <SEP> cholesterol <SEP> or <SEP> tri <tb> Decrease <SEP> (%) <SEP> in <SEP> serum <SEP> glyceride <SEP> (mg/ml) <SEP> in <SEP> the <tb> cholesterol <SEP> or <SEP> tri- <SEP> - <SEP> <SEP> 1 <SEP> - <SEP> medicated <SEP> group <tb> glyceride <SEP> = <SEP> <SEP> Serum <SEP> cholesterol <SEP> <SEP> or <SEP> trl- <SEP> <tb> <SEP> glyceride <SEP> (mg/ml) <SEP> in <SEP> the <tb> <SEP> control <SEP> group <tb> <SEP> Liver <SEP> weight <SEP> in <SEP> the <tb> Increase <SEP> (%) <SEP> in <SEP> liver <SEP> = <SEP> medicated <SEP> group <SEP> -1 <SEP> x <SEP> 100 <tb> weight <SEP> Liver <SEP> weight <SEP> in <SEP> the <tb> <SEP> control <SEP> group <tb> (ii) Preventive effect on lipid peroxide formation: An ethanol solution containing 10 3 or 10 4 M of a test compound was added to a mixture of 2.4 ml of 0.067 M potassium phosphate buffer solution (pH 7.4) and 0.5 ml of 10 % rat brain homogenate to adjust the final volume of the mixture to 3 ml. After 30-minute incubation of the mixture at 370C, one ml of 20 % trichloroacetic acid was added thereto, and lipid peroxide formation was determined by the thiobarbituric acid colorimetric method (J. Robak et al., Viochem. Pharmacol., Vol. 25, page 2233 (1976)). Suppression (%) of lipid peroxide formation of the test compound was calculated according to the following formula: EMI7.1 <tb> Suppression <SEP> (%) <SEP> # <SEP> OD <SEP> of <SEP> test <SEP> group* <SEP> <tb> of <SEP> lipid <SEP> peroxide <SEP> = <SEP> [ <SEP> 1 <SEP> - <SEP> # <SEP> OD <SEP> of <SEP> control <SEP> group** <SEP> ] <SEP> x <SEP> 100 <SEP> <tb> formation <tb> Note: * : group containing the test compound ** : group containing an equal volume of ethanol instead of the test compound solution #OD was calculated as 0(optical density measured at 532 nm) - (optical density measured at 600 nm)3 (Results) The results are shown in the following Table Table Decrease Decrease Increase Suppression (%) in (%) in increase (%) in lipid Test compounds serum serume (%) in peroxide trigly- choles- liver formation ceride terol weight 1 Dose 10-3M, 10-4M (The compounds of the present invention) -(4-methylbenzylthio- 48 14 0 72.7 10.2 carbonyl)-L-tryptophan N1-methyl-Nx-(benzyl- thiocarbonyl)-L- 30 15 5 65.2 9.0 tryptophan (Control) Clofibrate 34 26 14 24.3 0.5 Example 1 10.2 g of L-tryptophan and 10.1 g of triethylamine are dissolved in 50 ml of water, and 78 ml of a dioxane solution containing 3.0 g of carbonyl sulfide are added dropwise thereto at 50C to 100C for 15 minutes. The mixture is stirred at 100C for 15 minutes. Then, 7.0 g of 4-methylbenzyl chloride are added dropwise to the mixture at 100C for 10 minutes, and said mixture is" further stirred at room temperature for one hour. 'After the reaction, the mixture is condensed under reduced pressure to remove solvent. After the residue obtained is dissolved in a mixture of water and ether, the ether layer is removed thereform, and the aqueous layer is acidified with 10 % hydrochloric acid and then extracted with ethyl acetate. The extract is washed with water, dried and evaporated under reduced pressure to remove solvent. The residue thus obtained is crystallized with n-hexane, whereby 15.9 g of Ni-(4-methylbenzylthiocarbonyl)- L-tryptophan are obtained as pale yellow powder. Yield;86 % M.p. 111 - 1150C (gg 3 + 6.00(C=1.0, methanol) Elemental analysis calculated for C2oH2oN203S-1/2H2O C, 63.64; H,5.61; N, 7.41; S, 8.49 Found C, 64.18; H, 5.73; N, 7.78; S, 8.15 Example 2 5.5 g of N1-methyl-L-tryptophan and 5.1 g of triethylamine are dissolved in 25 ml of water, and 34 ml of a dioxane solution containing 1.5 g of carbonyl sulfide are added dropwise thereto at 50C to 100C for 15 minutes. The mixture is stirred at 100C for 15 minutes. Then, 3.2 g of benzyl chloride are added dropwise to the mixture at 100C for 10 minutes, and said mixture is further stirred at room temperature for 2 hours. After the reaction, the mixture is treated in the same manner as described in Example 1. 3.4 g of N1methyl-N&alpha;-benzylthiocarbonyl-L-tryptophan are thereby obtained as pale yellow powder. Yield: 37 % M.p. 85 - 870C +15.00 (C=1.0, methanol) IR #max.nujol (cm 1): 3300, 1720, 1670, 1500 Mass m/e : 368 (M+) NMR (CDCl3)i : 3.27(d, 2H, J=6.0Hz), 3.56(s, 3H), 4.10(s, 2H), 4.67 - 4.97(m, 1H), 6.05(d, 1H, J= 6.6Hz), 6.74(s, 1H), 6.92 - 7.56(m, 4H), 7.22 (s, 5H), 8.12(s, 1H)

Claims: What we claim is: 1. A tryptophan derivative of the formula: EMI10.1 wherein R1 is hydrogen or lower alkyl and R2 is phenyl or lower alkyl-phenyl, or a pharmaceutically acceptable salt thereof. 2. The compound of Claim 1, which R1 is hydrogen or methyl. 3. The compound of Claim 1, in which R2 is phenyl or 4-methylphenyl. 4. The compound of Claim 1, in which R1 is hydrogen or methyl, and R2 is phenyl or 4-methylphenyl. 5. The compound of Claim 4, in which R1 is hydrogen and R2 is 4-methylphenyl. 6. The compound of Claim 4, in which R1 is methyl and R2 is phenyl. 7. A process for preparing a compound of the formula: EMI10.2 wherein R1 is hydrogen or lower alkyl and R2 is phenyl or lower alkyl-phenyl, or a pharmaceutically acceptable salt thereof, which comprises the steps of: (A) reacting a compound of the formula: EMI11.1 wherein R1 is the same as defined above, with carbonyl sulfide (COS) and a benzyl halide of the formula: R2CH2X (III) wherein X is halogen and R2 is the same as defined above, or (B) reacting the compound (II) with a compound of the formula: R2CH2SCOX (IV) wherein R2 and X are the same as defined above, and (C) if required, further converting the product into a pharmaceutically acdeptable salt thereof. 8. The process according to Claim 7, wherein the reaction of the compound (II) with carbonyl sulfide and the compound (III) is carried out at a temperature between -300C and 500C in the presence of an acid acceptor in a solvent, or the reaction of the compound (II) with the compound (III) is carried out at a temperature between -500C and 500C in the presence of an acid acceptor in a solvent. 9. A pharmaceutical composition which comprises a compound of the formula: EMI12.1 wherein R1 is hydrogen or lower alkyl and R2 is phenyl or lower alkyl-phenyl, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier therefor.

Inventors: SAIGA, YUTAKA, SHIGEZANE, KEISUKE, TAKASHIMA, KOHKI
Applicants: TANABE SEIYAKU CO., LTD.
Application year: 1981
Main classification: C07D209
IPC codes: C07D209, A61P35, A61K31